How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug
Eli Lilly has become a victim of its own success — again. A dose of the popular diabetes treatment Mounjaro will have limited availability through February, highlighting a supply challenge that could put Wall Street’s loftiest sales goals for the drug and similar therapies in jeopardy. In a statement to […]
